We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current OXB market cap is 188.53M. The company's latest EPS is GBP -0.4676 and P/E is -4.14.
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Revenue | 66.78M | 64.06M | 87.73M | 142.8M | 139.99M |
| Operating Income | 6.63M | -12.84M | -5.49M | 20.82M | -51.56M |
| Net Income | 7.54M | -16.07M | -6.25M | 19.01M | -45.16M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Assets | 112.4M | 122.93M | 183.93M | 237.23M | 460.18M |
| Total Liabilities | 77.66M | 47.3M | 71.18M | 49.89M | 223.99M |
| Total Equity | 34.74M | 75.63M | 112.75M | 187.34M | 236.19M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Operating | 12.87M | -3.51M | 3.12M | 25.46M | -12.62M |
| Investing | -10.1M | -19.4M | -10.8M | -9.46M | -56.46M |
| Financing | 15.14M | 6.91M | 38.19M | 46.21M | 98.62M |
| Market Cap | 188.53M |
| Price to Earnings Ratio | -4.14 |
| Price to Sales Ratio | 1.34 |
| Price to Cash Ratio | 1.32 |
| Price to Book Ratio | 0.79 |
| Dividend Yield | - |
| Shares Outstanding | 96.58M |
| Average Volume (1 week) | 148.07k |
| Average Volume (1 Month) | 214.37k |
| 52 Week Change | -57.19% |
| 52 Week High | 473.00 |
| 52 Week Low | 164.40 |
| Spread (Intraday) | 1.2 (0.62%) |
| Company Name | Oxford Biomedica Plc |
| Address |
windrush court oxford OX4 6LT |
| Website | https://www.oxb.com |
| Industry | medicinal chems,botanicl pds (2833) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
